ACIU stock icon

AC Immune
ACIU

$4.26
11.21%
 

About: AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Employees: 161

0
Funds holding %
of 6,689 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

101% more call options, than puts

Call options by funds: $275K | Put options by funds: $137K

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

16% more funds holding

Funds holding: 32 [Q4 2023] → 37 (+5) [Q1 2024]

0.82% less ownership

Funds ownership: 30.01% [Q4 2023] → 29.2% (-0.82%) [Q1 2024]

42% less capital invested

Capital invested by funds: $148M [Q4 2023] → $85.7M (-$62.5M) [Q1 2024]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$8
88%
upside
Avg. target
$12
182%
upside
High target
$16
276%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
BTIG
Thomas Shrader
88%upside
$8
Buy
Initiated
31 May 2024
HC Wainwright & Co.
Andrew Fein
276%upside
$16
Buy
Reiterated
15 Mar 2024

Financial journalist opinion